v3.24.1.1.u2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Apr. 30, 2024
Oct. 31, 2023
Current assets:    
Cash and cash equivalents $ 995 $ 915
Short-term investments 22,244 22,929
Receivables 218 270
Prepaid expenses and other current assets 757 1,242
Total current assets 24,214 25,356
Operating lease right-of-use asset 141 166
Total assets 24,355 25,522
Current liabilities:    
Accounts payable 215 206
Accrued expenses 1,410 1,770
Operating lease liability 56 52
Total current liabilities 1,681 2,028
Operating lease liability, non-current 93 123
Total liabilities 1,774 2,151
Commitments and contingencies (Note 10)
Equity:    
Preferred stock, value
Common stock, par value $.01 per share; 100,000,000 shares authorized; 32,006,460 and 31,145,219 shares issued and outstanding as of April 30, 2024 and October 31, 2023, respectively 320 311
Additional paid-in capital 257,893 252,222
Accumulated deficit (234,590) (228,196)
Total shareholders’ equity 23,623 24,337
Noncontrolling interest (Note 2) (1,042) (966)
Total equity 22,581 23,371
Total liabilities and equity 24,355 25,522
Series A Convertible Preferred Stock [Member]    
Equity:    
Preferred stock, value

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL
v3.24.1.1.u2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Apr. 30, 2024
Apr. 30, 2023
Apr. 30, 2024
Apr. 30, 2023
Income Statement [Abstract]        
Revenue $ 210 $ 210
Operating costs and expenses:        
Inventor royalties, contingent legal fees, litigation and licensing expenses 161 161
Research and development expenses (including non-cash stock-based compensation expenses of $520, $492, $1,009 and $998, respectively) 1,646 998 2,995 2,066
General and administrative expenses (including non-cash stock-based compensation expenses of $740, $735, $1,511 and $1,292, respectively) 1,821 1,611 4,081 3,099
Total operating costs and expenses 3,467 2,770 7,076 5,326
Loss from operations (3,467) (2,560) (7,076) (5,116)
Interest income 287 253 606 455
Net loss (3,180) (2,307) (6,470) (4,661)
Less: Net loss attributable to noncontrolling interest (41) (19) (76) (51)
Net loss attributable to common shareholders $ (3,139) $ (2,288) $ (6,394) $ (4,610)
Net loss per common share attributable to common shareholders:        
Basic $ (0.10) $ (0.07) $ (0.20) $ (0.15)
Diluted $ (0.10) $ (0.07) $ (0.20) $ (0.15)
Weighted average common shares outstanding:        
Basic 31,914 30,930 31,677 30,924
Diluted 31,914 30,930 31,677 30,924

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL
v3.24.1.1.u2
Condensed Consolidated Statements Of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Apr. 30, 2024
Apr. 30, 2023
Reconciliation of net loss to net cash used in operating activities:    
Net loss $ (6,470) $ (4,661)
Stock option compensation to employees and directors 2,346 2,112
Stock options issued to consultants 78 128
Common stock issued to consultants 96 50
Amortization of operating lease right-of-use asset 25 23
Change in operating assets and liabilities:    
Receivables 52 (209)
Prepaid expenses and other current assets 485 286
Accounts payable 9 (69)
Accrued expenses (360) (433)
Operating lease liability (26) (22)
Net cash used in operating activities (3,765) (2,795)
Cash flows from investing activities:    
Disbursements to acquire short-term investments (34,738) (17,406)
Proceeds from maturities of short-term investments 35,423 13,377
Net cash provided by (used in) investing activities 685 (4,029)
Cash flows from financing activities:    
Proceeds from sale of common stock in an at-the-market offering, net of offering expenses 3,029
Proceeds from sale of common stock pursuant to an employee stock purchase plan 7 6
Proceeds from exercise of stock options 124 78
Net cash provided by financing activities 3,160 84
Net increase (decrease) in cash and cash equivalents 80 (6,740)
Cash and cash equivalents at beginning of period 915 12,360
Cash and cash equivalents at end of period $ 995 $ 5,620

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL